Literature DB >> 11286527

Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986--1996.

S Stewart1, K MacIntyre, M M MacLeod, A E Bailey, S Capewell, J J McMurray.   

Abstract

AIMS: Atrial fibrillation is a common and important cause of cardiovascular morbidity and mortality that may become more prevalent due to an ageing population and more prolonged exposure to predisposing cardiovascular disease states. This study examines recent trends in hospitalizations related to atrial fibrillation in Scotland. METHODS AND
RESULTS: Scotland (population 5.1 million) has a well described system for recording hospitalization data. All hospital discharges (and death) can be linked for each individual patient. We examined the period 1986--1996, during which time a total of 103,085 hospitalizations with a principal or secondary diagnosis of atrial fibrillation were recorded. The number of hospitalizations with a principal diagnosis of atrial fibrillation increased threefold from 1869 in 1986 to 5757 in 1996; the number with a secondary diagnosis rose from 3577 to 11,522. Similar increases were seen in the number of patients hospitalized, in those having a 'first-ever' hospitalization and in population hospitalization rates overall. The average age of patients rose, in men from 63.8 (SD 13.2) to 65.0 (13.2) years and in women from 72.2 (12.2) to 73.2 (11.4) years. The proportion of those aged >75 years rose from 33% to 35% in men and from 56% to 60% in women. Average length of stay and case fatality fell during this period, but, because of the overall increase in hospitalizations, atrial fibrillation contributed to a growing proportion of cardiovascular-related bed-days utilized (from 18% to 37% with atrial fibrillation coded in any diagnostic position).
CONCLUSION: The number of hospitalizations for atrial fibrillation has increased dramatically (two- to threefold) in recent years. These findings may be due to a real increase in atrial fibrillation prevalence, changing medical practice (e.g. coding or admission thresholds) or both. Consequently, the public health burden of atrial fibrillation is enormous. Moreover, the observed increase in atrial fibrillation-related hospital activity shows no sign of abating. Copyright 2001 The European Society of Cardiology.

Entities:  

Mesh:

Year:  2001        PMID: 11286527     DOI: 10.1053/euhj.2000.2511

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  25 in total

Review 1.  Implication from randomized trials of rate and rhythm controls on management of patients with persistent atrial fibrillation.

Authors:  Vincent E Hagens; Dirk J Van Veldhuisen; Harry J G M Crijns; Isabelle C van Gelder
Journal:  Ann Noninvasive Electrocardiol       Date:  2006-04       Impact factor: 1.468

Review 2.  Current perceptions of the epidemiology of atrial fibrillation.

Authors:  William B Kannel; Emelia J Benjamin
Journal:  Cardiol Clin       Date:  2009-02       Impact factor: 2.213

3.  Fibroblast growth factor-23 and incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS).

Authors:  Jehu S Mathew; Michael C Sachs; Ronit Katz; Kristen K Patton; Susan R Heckbert; Andrew N Hoofnagle; Alvaro Alonso; Michel Chonchol; Rajat Deo; Joachim H Ix; David S Siscovick; Bryan Kestenbaum; Ian H de Boer
Journal:  Circulation       Date:  2014-06-11       Impact factor: 29.690

Review 4.  Atrial fibrillation: current knowledge and future directions in epidemiology and genomics.

Authors:  Jared W Magnani; Michiel Rienstra; Honghuang Lin; Moritz F Sinner; Steven A Lubitz; David D McManus; Josée Dupuis; Patrick T Ellinor; Emelia J Benjamin
Journal:  Circulation       Date:  2011-11-01       Impact factor: 29.690

Review 5.  Challenges in the classification of atrial fibrillation.

Authors:  Steven A Lubitz; Emelia J Benjamin; Jeremy N Ruskin; Valentin Fuster; Patrick T Ellinor
Journal:  Nat Rev Cardiol       Date:  2010-06-22       Impact factor: 32.419

6.  Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting.

Authors:  Kostas Athanasakis; Eleftheria Karampli; Dimitrios Tsounis; Aikaterini Bilitou; John Kyriopoulos
Journal:  Clin Drug Investig       Date:  2015-11       Impact factor: 2.859

7.  Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop.

Authors:  Emelia J Benjamin; Peng-Sheng Chen; Diane E Bild; Alice M Mascette; Christine M Albert; Alvaro Alonso; Hugh Calkins; Stuart J Connolly; Anne B Curtis; Dawood Darbar; Patrick T Ellinor; Alan S Go; Nora F Goldschlager; Susan R Heckbert; José Jalife; Charles R Kerr; Daniel Levy; Donald M Lloyd-Jones; Barry M Massie; Stanley Nattel; Jeffrey E Olgin; Douglas L Packer; Sunny S Po; Teresa S M Tsang; David R Van Wagoner; Albert L Waldo; D George Wyse
Journal:  Circulation       Date:  2009-02-03       Impact factor: 29.690

Review 8.  The heart failure epidemic.

Authors:  Véronique L Roger
Journal:  Int J Environ Res Public Health       Date:  2010-04-19       Impact factor: 3.390

Review 9.  Status of the epidemiology of atrial fibrillation.

Authors:  William B Kannel; Emelia J Benjamin
Journal:  Med Clin North Am       Date:  2008-01       Impact factor: 5.456

Review 10.  Epidemiology of heart failure.

Authors:  Véronique L Roger
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.